The partnership will support the development of novel technologies in drug discovery, accelerate scientific talents across Canada, and advance Canada’s position as an international leader for healthcare innovation.
Category: Press Release
The partnership will significantly enrich GlycoNet’s and API’s capacities to support companies with innovations in glycomics.
GlycoNet researchers discovered a molecule against Methicillin-resistant (MRSA) bacteria.
Projects seek solutions to health issues including heart disease, infections, cancer and diabetes
As the province’s leadership in glycomics research grows, investigators continue to work to answer important questions about human and animal health
Drs. Alexey V. Pshezhetsky and Christopher Cairo awarded half a million dollars to advance research on inhibitors to treat cardiovascular and autoimmune diseases.
Glycomics researcher Lara Mahal announced as Canada Excellence Research Chair.
GlycoNet awards $1.45 million to eight projects aimed at improving the health of Canadians. Funding supports glycomics translational research into post-surgical pain management, cancer diagnosis, and treatment of Parkinson’s disease, infectious diseases and chronic illness.
Glyco-based companies use funds to protect intellectual property, build business capacity EDMONTON (October 9, 2018) – The Canadian Glycomics Network (GlycoNet) awarded $90,000 in grants to three Alberta-based startup companies: 48Hour Discovery Inc., GlyCa BioSciences Inc. and PanTHERA CryoSolutions Inc. The Startup Company Funding Program recognizes the needs of start-up companies and provides financial help […]
MINNEAPOLIS, March 15, 2018 (GLOBE NEWSWIRE) — Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), formerly Skyline Medical, announced today that its wholly owned subsidiary, TumorGenesis Inc., has secured a license agreement with 48Hour Discovery (“48HD”) which grants it access to 48HD’s ligand discovery technology. This follows a license agreement with SyntArray, LLC, announced on March 13th, and […]